2nd November, 2026

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: NSE - KILITCH

Sub: Intimation of the Board Meeting

Dear Sir,

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the meeting of the Board of Directors of the Company will be held on Friday, 6th November, 2026 inter-alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September, 2026.

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE and Company's code of conduct for Prevention of Insider Trading, the Trading Window has been closed with effect from 1st October, 2026 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND PRATAPRAI MEHTA
Digitally signed by MUKUND PRATAPRAI MEHTA
Date: 2026.11.02 16:13:10 +05'30'

Mukund Mehta
Managing Director
DIN: 00147876

ISO 9001:2008 13485:2003 WHO CERTIFIED EXPORT HOUSE RECOGNISED BY GOVT OF INDIA BQ INDIA Pharmacy of the World